-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China has announced that the IMG-020 injection declared by Chuangxiang Biotechnology has obtained an implied license for a clinical trial and plans to develop a treatment for ankylosing spondylitis.
The Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China has announced that the IMG-020 injection declared by Chuangxiang Biotechnology has obtained an implied license for a clinical trial and plans to develop a treatment for ankylosing spondylitis.
In May 2020, Chuangxiang Bio announced that it has reached a global cooperation agreement with Affibody, and has obtained the exclusive development and commercialization rights of IMG-020 in Greater China (Mainland China, Hong Kong, Macau, Taiwan), South Korea and other countries and regions.
According to a press release issued by Chuangxiang Bio, currently, IMG-020 has successfully completed a phase 2 clinical trial for psoriasis in Germany.
This time, the clinical research indication approved by IMG-020 in China is ankylosing spondylitis.